TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06418568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra-pulsed Shockwave Therapy Device by Shenzhen Lifotronic Technology Co., Ltd.
Description: The intervention involves treating melasma using tranexamic acid (aminomethylbenzoic acid) delivered through ultra-pulsed shockwave therapy on one side of the face, while the other side receives topical application of tranexamic acid at the same concentration. The shockwave therapy parameters are tailored based on patient tolerance. Each patient undergoes 3 treatment sessions spaced 3 weeks apart, followed by a 4-week follow-up period. Facial skin is assessed using the VISIA system before each treatment and at the 4-week follow-up, evaluating the Melasma Area Severity Index (MASI). Patient and researcher satisfaction levels are rated on a scale of 1 to 5. Adverse reactions, including short-term effects like pain and swelling, and potential long-term effects such as allergic reactions and hyperpigmentation, are monitored after each treatment session.
Study: NCT05163834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod
Description: intravenous infusion of efgartigimod

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod
Description: intravenous infusion of efgartigimod

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion of placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOVAX 23
Description: PNEUMOVAX 23 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOVAX 23
Description: PNEUMOVAX 23 vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PNEUMOVAX 23
Description: PNEUMOVAX 23 vaccine
Study: NCT06207071

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA
Description: DHA supplementation
Study: NCT04905823

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: assessment of humoral, immune cell response and glycemia

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: assessment of humoral, immune cell response and glycemia

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: assessment of humoral, immune cell response and glycemia
Study: NCT03177746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine/Tadalafil 30/20 mg film coated tablet
Description: During 4-weeks treatment period, patients will take one Dapoxetine/Tadalafil 30/20 mg film coated tablet 1-3 hours before sexual intercourse.~Study drug should not be used more than 1 tablet every 24 hours during the treatment.
Study: NCT06154148

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional prone position
Description: The infant is placed vertically between the mother's breasts firmly attached to the chest and below their clothes.
Study: NCT05761808

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Description: Before being included in the study, the multifudus muscle thickness at the L4-L5 level of each patient will be measured ultrasonographically. First of all, exercises to learn transversus abdominis activation will be performed in patients. They will then be included in the stretching and strengthening exercise program. Stretching and strengthening exercises were planned as dynamic abdominal bracing, finding and maintaining neutral position, and exercises on all fours. Exercise therapy will be applied by the same physiotherapist 3 days a week for 5 weeks. Patients will continue to exercise for 7 more weeks as a home program. During this period, they will be called once a week by phone.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neuromuscular electrical stimulation
Description: NMES intensity will be planned individually according to the patients. Before being included in the study, the multifudus muscle thickness at the L4-L5 level of each patient will be measured ultrasonographically. NMES application will be applied by a specialist physiotherapist 3 days a week for 5 weeks, for a total of 15 sessions. Exercises will be applied 3 days a week for 5 weeks, accompanied by a physiotherapist. Patients will continue to exercise for 7 more weeks as a home program. In this process, patients will be called once a week by phone.
Study: NCT06237712

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement consisting of 40 mmol/daily of potassium chloride
Description: The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement consisting of 40 mmol/daily of potassium gluconate
Description: The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement consisting of 40 mmol/daily of potassium bicarbonate
Description: The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement consisting of 40 mmol/daily of sodium chloride
Description: The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement consisting of 40 mmol/daily of sodium bicarbonate
Description: The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo caps
Description: The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
Study: NCT05373758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care treatment strategy
Description: Management of virologic failure on TLD using the Standard of Care strategy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Care treatment strategy
Description: Management of virologic failure on TLD using the Individualized Care strategy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate Switch
Description: Management of virologic failure on TLD using the Immediate Switch strategy
Study: NCT01006096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 100mg tablet, once daily for 16 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet
Description: placebo tablet (lactose), once daily for 16 weeks
Study: NCT05599412

Intervention type: DRUG
Intervention: Lorviqua
Description: As provided in real world practice
Study: NCT06556667

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biphasic defibrillator with maximum energy of 200J (® Zoll)
Description: Cardioversion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biphasic defibrillator with maximum energy of 360J (® Physio-Control)
Description: Cardioversion
Study: NCT05247125

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Blue light exposure + Melatonin treatment
Description: 3 mg Melatonin pill will be given 1 hour before going to bed. Blue light exposure will be performed during 30-minute sessions with the use of the lamps (Lumie/Vitamin L) in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Description: 3 mg Melatonin pill will be given 1 hour before going to bed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue light exposure
Description: Blue light exposure will be performed during 30-minute sessions with the use of the lamps (Lumie/Vitamin L) in the morning.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo light exposure will be performed by using lamp turned off; and placebo pill will be given in the evening
Study: NCT06006936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping with Infertility Self-Help Program
Description: The CWI program consists of seven 10-minute videos, each with accompanying homework assignments.~The first module, cognitive restructuring, includes instructions on challenging extreme or unhelpful automatic thoughts. The second module, challenging negative core beliefs, includes looking for patterns in thinking that illustrate core beliefs. The third module features behavioural activation techniques and emphasizes the importance of regular pleasure and skill-based activities. The fourth module highlights coping with grief and factors that contribute to grief, such as individual differences in grieving style. The fifth module supports strengthening relationships through responding to requests for affection and outlines several common relationship mistakes. The sixth module demonstrates how to identify and use values to make decisions and guide behaviour. The seventh module summarizes how thoughts, actions, and interactions can contribute to well-being when experiencing infertility.
Study: NCT05506072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction therapy
Description: Blood Flow Restriction involves the application of a tourniquet to an extremity to partially restrict the arterial and venous blood flow to stimulate localized cellular and systemic hormonal changes that occur in high intensity exercise. BFR Training may produce similar cellular and muscular responses to cause hypertrophy when exercise is performed at low intensity. Studies have compared BFR therapy in the lower extremities with light load resistance exercise to light load resistance alone and observed greater improvements in the BFR group. A recent systematic review further identified that adding BFR to exercise effectively augments muscle strength and size. Additionally, BFR has been shown to be applied in a safe manner with low risk for complications. With this growing body of evidence supporting BFR, it is becoming increasingly common in rehabilitation
Study: NCT05678933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine (75mg/ m2) will be administered at day 1-5 by subcutaneous injection of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide (20 mg) will be taken orally twice a week for two weeks of each 21-day cycle.
Study: NCT05506072

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood flow restriction therapy
Description: Blood Flow Restriction involves the application of a tourniquet to an extremity to partially restrict the arterial and venous blood flow to stimulate localized cellular and systemic hormonal changes that occur in high intensity exercise. BFR Training may produce similar cellular and muscular responses to cause hypertrophy when exercise is performed at low intensity. Studies have compared BFR therapy in the lower extremities with light load resistance exercise to light load resistance alone and observed greater improvements in the BFR group. A recent systematic review further identified that adding BFR to exercise effectively augments muscle strength and size. Additionally, BFR has been shown to be applied in a safe manner with low risk for complications. With this growing body of evidence supporting BFR, it is becoming increasingly common in rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physical Thearapy
Description: Participants will be randomized into their assigned group of receiving standard therapy without BFR by a blinded therapist within the study using a computer generated randomization formula Participants will then visit the clinic for study testing at six weeks, 12 weeks, and six months after their surgery. During each of these visits, they will be asked to complete a survey, and then their shoulder strength and flexibility will be measured. Each study visit will last approximately 30 minutes. Participants will also attend 12-18 shoulder rehabilitation sessions in the clinic over six weeks from the six week to 12 week mark (about two to three sessions per week). Each rehabilitation session will last approximately 30 minutes and consist of standard rehabilitation exercises without BFR.~Between the 12-week follow-up and 6-month follow-up, participants will receive standard post-surgical rehabilitation for their specific shoulder surgery without Blood Flow Restriction training.
Study: NCT06353152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection
Description: single-/multiple-dose infusion
Study: NCT05678933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin (70mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin (70mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
Study: NCT06216327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: household safety intervention
Description: This intervention includes a household safety intervention that is delivered by an interventionist with specific training in facilitating lethal means safety discussions, and the provision of no-cost safety devices for medications and firearms.
Study: NCT05415254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Calcitriol supplementation orally
Study: NCT04531956

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic decision aid s-decided
Description: The intervention will consist of implementing a patient decision aid (PtDA) in general practice. The patient decision aid will be developed in line with the systematic development process specified by the International Patient Decision Aids Standards (IPDAS)
Study: NCT05437952

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taurine and Exercise (Tau+Ex)
Description: Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.~Pshysical exercise~Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo and Exercise (PL+Ex)
Description: Participants will receive 3g of placebo to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.~Pshysical exercise~Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taurine (Tau)
Description: Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PL)
Description: Participants will receive 3g of placebo to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
Study: NCT05255835

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Semiconductor Knee Sleeves
Description: semiconductor elements germanium and carbon within the cotton fabric

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cotton Knee Sleeves (Placebo)
Description: cotton fabric knee sleeves
Study: NCT05634382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis agents
Description: Intravenous thrombolysis with recombinant tissue-type plasminogen activator (rt-PA，alteplase) or TNK-tPA (Tenecteplase，Metalyse)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endovascular thrombectomy
Description: endovascular mechanical thrombectomy with nonspecific device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endovascular thrombectomy
Description: endovascular mechanical thrombectomy with nonspecific device
Study: NCT04952428

Intervention type: BEHAVIORAL
Intervention: Re-examination visit (today visit)
Description: Re-examination visit (today visit) A guidebook will be prepared to standardize procedures throughout the protocol, step by step, for all questionnaires and evidence collection. The data will be transferred to a computerized database.~The clinician will review with the patient the Information and Medication History Forms and record the anthropometric, socio-demographic and clinical information. Candidates will undergo an oral pathology examination and a full-mouth manual probing using a periodontal probe SONDA PA_ON (Orange Dental®, Aspachstr, Biberach, Germany) to determine their periodontal and peri-implant status. Clinical and radiographic examination will be performed. Moreover, signs as presence of suppuration, bleeding, redness, probing depth must be recorded at 6 sites per implant applying. As well, a specific survey about tobacco habits including modification of Fagestrom \& Richmond test will be conducted.

Intervention type: BEHAVIORAL
Intervention: Re-examination visit (today visit)
Description: Re-examination visit (today visit) A guidebook will be prepared to standardize procedures throughout the protocol, step by step, for all questionnaires and evidence collection. The data will be transferred to a computerized database.~The clinician will review with the patient the Information and Medication History Forms and record the anthropometric, socio-demographic and clinical information. Candidates will undergo an oral pathology examination and a full-mouth manual probing using a periodontal probe SONDA PA_ON (Orange Dental®, Aspachstr, Biberach, Germany) to determine their periodontal and peri-implant status. Clinical and radiographic examination will be performed. Moreover, signs as presence of suppuration, bleeding, redness, probing depth must be recorded at 6 sites per implant applying. As well, a specific survey about tobacco habits including modification of Fagestrom \& Richmond test will be conducted.

Intervention type: BEHAVIORAL
Intervention: Re-examination visit (today visit)
Description: Re-examination visit (today visit) A guidebook will be prepared to standardize procedures throughout the protocol, step by step, for all questionnaires and evidence collection. The data will be transferred to a computerized database.~The clinician will review with the patient the Information and Medication History Forms and record the anthropometric, socio-demographic and clinical information. Candidates will undergo an oral pathology examination and a full-mouth manual probing using a periodontal probe SONDA PA_ON (Orange Dental®, Aspachstr, Biberach, Germany) to determine their periodontal and peri-implant status. Clinical and radiographic examination will be performed. Moreover, signs as presence of suppuration, bleeding, redness, probing depth must be recorded at 6 sites per implant applying. As well, a specific survey about tobacco habits including modification of Fagestrom \& Richmond test will be conducted.
Study: NCT05754411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]STI-1558
Description: Fasting oral administration of 600 mg \[ 14C \] STI-1558 ( about 100 μCi ) solution.
Study: NCT05965245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suubi-Mhealth
Description: Suubi-Mhealth is a theoretically-based digital therapeutics tool that aims to provide educational content on depression while considering the unique needs of SSA youth living with HIV. This educational content will be aligned with scientific recommendations for cognitive-behavioral therapy for adherence and depression as applied to HIV medication adherence. Core instruction will include psychoeducation on the interplay between HIV and depression; minimizing cognitive distortions related to ART adherence and stigma, as well as depression; challenging negative automatic thoughts; analysis and development of behavioral skills; reducing environmental stressors. Suubi-Mhealth will also have a social networking center in which patients can contact the research team, peers who are also taking part in this intervention, and other trusted individuals such as loved ones. Other features include tools for setting and monitoring goals, and a clinical management dashboard for the research team.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Suubi-Mhealth
Description: Suubi-Mhealth is a theoretically-based digital therapeutics tool that aims to provide educational content on depression while considering the unique needs of SSA youth living with HIV. This educational content will be aligned with scientific recommendations for cognitive-behavioral therapy for adherence and depression as applied to HIV medication adherence. Core instruction will include psychoeducation on the interplay between HIV and depression; minimizing cognitive distortions related to ART adherence and stigma, as well as depression; challenging negative automatic thoughts; analysis and development of behavioral skills; reducing environmental stressors. Suubi-Mhealth will also have a social networking center in which patients can contact the research team, peers who are also taking part in this intervention, and other trusted individuals such as loved ones. Other features include tools for setting and monitoring goals, and a clinical management dashboard for the research team.
Study: NCT05271734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lid retractor placement
Description: Insertion of a lid retractor to find out if the corneal limbus is exposed in 360 degress
Study: NCT05310916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab plus another oral hypoglycemic agent
Description: Dapagliflozin is a member of Sodium-glucose co-transporter 2 inhibitors class which in addition to its glucose control effect, has reno-protective and cardioprotective effects, controls blood pressure and causes weight loss.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two oral hypoglycemic agents other than dapagliflozin
Description: Two oral anti-diabetic agents not including sodium-glucose co-transporter 2 inhibitors